Canakinumab in the treatment active hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS)

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Juan Ignacio Aróstegui Gorospe, MD, PhD, from the Hospital Clínic de Barcelona, Barcelona, Spain, discusses the efficacy and safety of canakinumab in active hyperimmunoglobulinaemia D with periodic fever syndrome (HIDS) and the implications of the results for the future treatment of patients with the condition.